Original Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 14, 2013; 19(14): 2154-2161
Published online Apr 14, 2013. doi: 10.3748/wjg.v19.i14.2154
Table 5 Comparison of treatment approaches in the first and second series of treatments in metastatic gastric cancer patients
1st-series treatment approachP value2nd-series treatment approachP value
DCF vs 5-FU-LV0.043DCF vs ECF0.050
DCF vs others0.010DCF vs Supportive0.042
DCF vs Supportive< 0.001Supportive vs ECF0.500
DCF vs ECF< 0.001DCF vs others0.605
DCF vs CF0.480Irinotecan/Cisp vs ECF0.423
ECF vs CF0.960Supportive vs Irinotecan/Cisp0.100
Supportive vs ECF< 0.01DCF vs Irinotecan/Cisp0.672